Naos (Salbutamol Sulfate, Ipratropium Bromide)

Salbutamol activates β2‑adrenergic receptors on airway smooth muscle, triggering a cascade that raises cyclic AMP and causes muscle relaxation. Ipratropium blocks muscarinic M3 receptors, preventing acetylcholine‑mediated contraction. By simultaneously stimulating bronchodilation and inhibiting bronchoconstriction, the two agents produce a synergistic widening of the airways.

The dose of Naos is individualized by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Typical regimens involve a specific number of inhalations per dose and a defined frequency, but exact dosing instructions must be obtained from the prescriber’s order.

Safety data for Naos in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case and discuss potential risks and alternatives with the patient.

To request Naos, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

A single‑component inhaler contains either a β2‑agonist or an anticholinergic agent, providing bronchodilation through one pathway. Naos combines both mechanisms in one device, offering broader airway relaxation, potentially faster symptom control, and the convenience of a single inhaler, which can improve adherence compared with using two separate products.

Naos should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the inhaler cap closed when not in use and avoid exposing the device to extreme temperatures or humidity, which could affect aerosol performance.

Naos is delivered via inhalation using a metered‑dose inhaler. The patient should shake the device, exhale fully, place the mouthpiece in the mouth, and inhale slowly and deeply while actuating the inhaler. After each puff, hold the breath for several seconds before exhaling. Proper technique should be demonstrated by a healthcare professional.

Serious adverse events, although rare, include paradoxical bronchospasm, angioedema, and significant tachycardia or other cardiac arrhythmias. If any of these occur, the patient should seek immediate medical attention, discontinue the inhaler, and inform their healthcare provider promptly.

Naos is contraindicated in patients with a known hypersensitivity to salbutamol, ipratropium, or any excipients in the formulation. Caution is also advised for individuals with severe cardiovascular disease, uncontrolled narrow‑angle glaucoma, or those taking non‑selective β‑blockers, as these conditions may increase the risk of adverse reactions.